Human immune cell composition of TME depends on tumor cell line-derived xenograft subtype and tumor burden in genO-BRGSF-HIS mice
TME composition in genO-BRGSF-HIS mice
Background
The relevance of preclinical models has vastly improved with mice bearing a human immune system, especially in the context of immunotherapy. genO-BRGSF (BALB/c Rag2-/-, IL2Rγ-/-, SIRPαNOD and Flt3-/-) is a highly immunodeficient mouse featuring reduced murine myeloid cells. genO-BRGSF mice reconstituted with human cord blood CD34+ cells (genO-BRGSF-HIS) develop functional lymphoid and myeloid compartments. This engraftment is stable for over a year(1) and mice do not develop GvHD. Additionally, t h e myeloid compartment can be transiently boosted with exogenous human Flt3L injections. In contrast to other models that overexpress human cytokines to develop human myeloid cells, Flt3L-treated genO-BRGSF-HIS mice do not show side effects. genO-BRGSF-HIS mice are permissive to mouse and human cancer cell line engraftment, hence representing a valuable preclinical model to study cancer development and evaluate novel therapeutics.
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe